Silvana Canevari

Jul 25, 2023 | nature.com | James B. Spicer |Udai Banerji |Rebecca S Kristeleit |Rowan Miller |Christopher J Corrigan |Silvana Canevari | +8 more

AbstractAll antibodies approved for cancer therapy are monoclonal IgGs but the biology of IgE, supported by comparative preclinical data, offers the potential for enhanced effector cell potency. Here we report a Phase I dose escalation trial (NCT02546921) with the primary objective of exploring the safety and tolerability of MOv18 IgE, a chimeric first-in-class IgE antibody, in patients with tumours expressing the relevant antigen, folate receptor-alpha.